Back to clinical trials listHématologie / cancers du sang

MO44869_GLOASIS

https://clinicaltrials.gov/study/NCT06558604?term=gloasis&rank=1

Open at Saint-Cloud since : 18/02/2025
Target : Adult
Phase : Phase II

Trial description

The primary efficacy endpoint is PFS (progression-free survival) at 12 months (end of C17) from the first dose of the study treatment, as determined by central imaging review (Lugano 2014 criteria). Each cohort will be assessed independently.

Url of the trial

Main investigator

STEVEN LE GOUILL

Professeur - Médecin

Contact